

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 July 2023 (20.07.2023)



(10) International Publication Number
WO 2023/134732 A1

(51) International Patent Classification:

A61K 31/60 (2006.01) A61P 9/10 (2006.01)
C07C 235/42 (2006.01)

(21) International Application Number:

PCT/CN2023/071973

(22) International Filing Date:

12 January 2023 (12.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/072270

17 January 2022 (17.01.2022) CN

(71) Applicants: **TECHFIELDS PHARMA CO., LTD.**

[CN/CN]; Room 101, Building 9, 168 Majian Road, Gaoxin District, Suzhou, Jiangsu 215129 (CN). **TECHFIELDS INC.** [US/US]; 731 Alexander Road, Princeton, New Jersey 08540 (US).

(72) Inventors: **YU, Chongxi**; 731 Alexander Road, Suite 205,

Princeton, New Jersey 08540 (US). **XU, Lina**; 168 Majian Road, Building 9, Room 401, Gaoxin District, Suzhou, Jiangsu 215129 (CN).

(74) Agent: **BEIJING WANHUIDA LAW FIRM**; 2F, Yiyuan

Office, Friendship Hotel, No.1 Zhongguancun Street South, Haidian District, Beijing 100873 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS




Figure 1

(57) Abstract: It provides 2- (diethylamino) ethyl acetoxybenzoate hydrochloride, other high penetration prodrugs of aspirin and other NSAIDs, and pharmaceutically acceptable salts thereof for use and methods thereof in the prevention or treatment of cardiovascular diseases and conditions. Pharmaceutical compositions, treatment kits and devices comprising 2- (diethylamino) ethyl acetoxybenzoate hydrochloride, other high penetration prodrugs of aspirin and other NSAIDs, and pharmaceutically acceptable salts thereof, as well as dosage forms, dosages, and methods of use thereof through topical administration are disclosed.

WO 2023/134732 A1